Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types
2020 Annals of Translational Medicine. All rights reserved..
BACKGROUND: Tumor mutation burden (TMB) has an important association with immunotherapy responses. TMB in the Chinese population has not been well established. Finding differences between the Chinese and Caucasian populations and elucidating the underlying biological mechanisms of high TMB might help develop more precise and effective means for TMB and immunotherapy response prediction.
METHODS: Chinese cancer patients fresh tissue (n=2,177), formalin-fixed, paraffin-embed (FFPE) specimens (n=3,294), and pleural fluid (n=189) were profiled using a 295- or 520-gene next-generation sequencing (NGS) panel. The association of the TMB status with a series of molecular features and biological pathways was determined using bootstrapping.
RESULTS: TMB, measured by 295- or 520-cancer-related gene panels, was correlated with whole-exome sequencing (WES) TMB based on the in silico simulation in The Cancer Genome Atlas cohort. The median TMB of our data was slightly higher than that from the Foundation Medicine Inc. (FMI) dataset. TMB was also slightly different within the same cancer type between the Chinese and Caucasian population. We discovered that the underlying pathways of TMB status varied greatly and sometimes had an opposite association with TMB across different cancer types. Moreover, we developed a 23-gene and a 16-gene signature to predict TMB prediction for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), respectively, indicating a histology-specific mechanism for driving high-TMB in lung cancer.
CONCLUSIONS: TMB varies among different ethnic populations. Our findings extend the knowledge of the underlying biological mechanisms for high TMB and might be helpful for developing more precise and accessible TMB assessment panels and algorithms in more cancer types.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Annals of translational medicine - 8(2020), 14 vom: 05. Juli, Seite 860 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiao, Xiao-Dong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer-related gene panel |
|---|
| Anmerkungen: |
Date Revised 16.04.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/atm-20-3807 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31368376X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31368376X | ||
| 003 | DE-627 | ||
| 005 | 20231225151111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/atm-20-3807 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM31368376X | ||
| 035 | |a (NLM)32793704 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiao, Xiao-Dong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2020 Annals of Translational Medicine. All rights reserved. | ||
| 520 | |a BACKGROUND: Tumor mutation burden (TMB) has an important association with immunotherapy responses. TMB in the Chinese population has not been well established. Finding differences between the Chinese and Caucasian populations and elucidating the underlying biological mechanisms of high TMB might help develop more precise and effective means for TMB and immunotherapy response prediction | ||
| 520 | |a METHODS: Chinese cancer patients fresh tissue (n=2,177), formalin-fixed, paraffin-embed (FFPE) specimens (n=3,294), and pleural fluid (n=189) were profiled using a 295- or 520-gene next-generation sequencing (NGS) panel. The association of the TMB status with a series of molecular features and biological pathways was determined using bootstrapping | ||
| 520 | |a RESULTS: TMB, measured by 295- or 520-cancer-related gene panels, was correlated with whole-exome sequencing (WES) TMB based on the in silico simulation in The Cancer Genome Atlas cohort. The median TMB of our data was slightly higher than that from the Foundation Medicine Inc. (FMI) dataset. TMB was also slightly different within the same cancer type between the Chinese and Caucasian population. We discovered that the underlying pathways of TMB status varied greatly and sometimes had an opposite association with TMB across different cancer types. Moreover, we developed a 23-gene and a 16-gene signature to predict TMB prediction for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), respectively, indicating a histology-specific mechanism for driving high-TMB in lung cancer | ||
| 520 | |a CONCLUSIONS: TMB varies among different ethnic populations. Our findings extend the knowledge of the underlying biological mechanisms for high TMB and might be helpful for developing more precise and accessible TMB assessment panels and algorithms in more cancer types | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chinese | |
| 650 | 4 | |a Tumor mutation burden (TMB) | |
| 650 | 4 | |a cancer-related gene panel | |
| 650 | 4 | |a gene signature | |
| 700 | 1 | |a Zhang, Xiao-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Bao-Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Ni, Jian-Jiao |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Zhou-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ling-Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Liang-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Song-Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Shen-Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xue-Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ai-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Han-Zhang, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Junyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Chuai, Shannon |e verfasserin |4 aut | |
| 700 | 1 | |a Zang, Yuan-Sheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of translational medicine |d 2013 |g 8(2020), 14 vom: 05. Juli, Seite 860 |w (DE-627)NLM23455374X |x 2305-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:14 |g day:05 |g month:07 |g pages:860 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/atm-20-3807 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 14 |b 05 |c 07 |h 860 | ||